Exploring non-invasive diagnostics for metabolic dysfunctionassociated fatty liver disease

作     者：Biao Qu Zheng Li 

作者机构：Department of Clinical PharmacologyThe Second Hospital of Anhui Medical UniversityHefei 230601Anhui ProvinceChina Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial CellsCollege of Health SciencesSchool of Life SciencesJiangsu Normal UniversityXuzhou 221000Jiangsu ProvinceChina 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2024年第30卷第28期

页      面：3447-3451页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by The National Natural Science Foundation of China No.82104525 

主　　题：Metabolic dysfunction-associated fatty liver disease Non-invasive diagnostics Circulating biomarkers Imaging biomarkers Stool microbial biomarkers 

摘      要：The population with metabolic dysfunction-associated fatty liver disease(MAFLD)is increasingly common *** of people at risk of progression to advanced stages is necessary to timely offer interventions and appropriate *** biopsy is currently considered the gold standard for the diagnosis and staging of MAFLD,but it has associated risks and *** has spurred the exploration of non-invasive diagnostics for MAFLD,especially for steatohepatitis and *** non-invasive approaches mostly include biomarkers and algorithms derived from anthropometric measurements,serum tests,imaging or stool metagenome ***,they still need rigorous and widespread clinical validation for the diagnostic performance.